Research
Hormonal
Discontinuation of GLP-1 RA treatment leads to significant weight regain (up to 68% of lost weight) and reversal of cardiometabolic improvements, indicating that obesity requires chronic management.
If you stop taking GLP-1 medications, you will likely regain most of the weight you lost, along with your previous metabolic risks. This is because obesity is a chronic condition, not a temporary state. Just as you wouldn't stop blood pressure medication, you likely need to stay on GLP-1 therapy long-term to maintain your weight loss. The goal is sustained health, not a short-term fix.
StrongSupportsHIGH confidence
In an extension of the STEP-1 trial, participants originally randomized to semaglutide regained 68% of their lost weight after one year of discontinuing treatment... Cardiometabolic improvements achieved with semaglutide also reverted towards baseline for most risk factors after one year.
Why this rating
Based on STEP-1 and STEP-4 trial extensions.
Source
The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions
Areesha Moiz et al. · EClinicalMedicine · 2025
narrative_reviewCited 68×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →